One out of the three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 217 points (1.3%) at 16,418 as of Friday, Sept. 25, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,782 issues advancing vs. 1,190 declining with 158 unchanged.

The Drugs industry currently sits down 2.9% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include

bluebird bio

(

BLUE

), down 9.0%,

Alnylam Pharmaceuticals

(

ALNY

), down 7.0%,

Medivation

(

MDVN

), down 5.8%,

Incyte

(

INCY

), down 2.7% and

Illumina

(

ILMN

), down 2.5%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Celgene

(

CELG

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Celgene is down $1.64 (-1.4%) to $112.24 on average volume. Thus far, 3.0 million shares of Celgene exchanged hands as compared to its average daily volume of 5.0 million shares. The stock has ranged in price between $112.15-$115.68 after having opened the day at $115.68 as compared to the previous trading day's close of $113.88.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. Celgene has a market cap of $92.5 billion and is part of the health care sector. The company has a P/E ratio of 44.3, above the S&P 500 P/E ratio of 24.3. Shares are up 1.8% year-to-date as of the close of trading on Thursday. Currently there are 13 analysts that rate Celgene a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Celgene

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Celgene Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Pfizer

(

PFE

) is down $0.30 (-0.9%) to $32.40 on average volume. Thus far, 9.7 million shares of Pfizer exchanged hands as compared to its average daily volume of 24.8 million shares. The stock has ranged in price between $32.39-$33.10 after having opened the day at $32.96 as compared to the previous trading day's close of $32.70.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Pfizer has a market cap of $201.2 billion and is part of the health care sector. The company has a P/E ratio of 23.1, below the S&P 500 P/E ratio of 24.3. Shares are up 5.0% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Pfizer

as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Pfizer Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Gilead

(

GILD

) is down $0.51 (-0.5%) to $102.00 on average volume. Thus far, 4.5 million shares of Gilead exchanged hands as compared to its average daily volume of 10.8 million shares. The stock has ranged in price between $101.90-$104.19 after having opened the day at $104.03 as compared to the previous trading day's close of $102.51.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $154.8 billion and is part of the health care sector. The company has a P/E ratio of 11.1, below the S&P 500 P/E ratio of 24.3. Shares are up 8.8% year-to-date as of the close of trading on Thursday. Currently there are 13 analysts that rate Gilead a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Gilead

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Gilead Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).